Executive Summary
Curidium Medica plc (formerly Cielo Holdings plc) is a drug discovery and development company focussed on identifying targeted medicines to treat patients more effectively. Curidium has developed a novel and proprietary technology, Homomatrix, to establish the underlying mechanisms of human diseases. Curidium's technology identifies different patient subgroups each having a distinct disease mechanism. This enables the generation of new diagnostic tools and medicines designed for a subgroup of patients and potentially offering improved safety and effectiveness. Curidium is focusing its core technology to diseases of the Central Nervous System (CNS). Curidium has developed a pipeline of four clinical candidates to treat diseases, which were previously developed for other indications and the directors believe that Curidium's approach to re-develop existing drugs as targeted medicines for the appropriate patient group may reduce clinical trial cost, development timelines and regulatory risks. Curidium's directors believe it to be one of the most advanced companies identifying targeted medicines for CNS disorders and to generate shareholder value Curidium follows a diversified commercialisation model by building partnerships through 1) strategic research alliances and 2) product licensing agreements.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
